New preclinical data to be presented on
- Core inhibitor EDP-514 targeting HBV
- FXR agonist EDP-305 targeting NASH
- ASK-1 inhibitors EP-026856 and EP-027315 targeting NASH
WATERTOWN, Mass.–(BUSINESS WIRE)–Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and
development-focused biotechnology company dedicated to creating small
molecule drugs for viral infections and liver diseases, today announced
that new preclinical data from Enanta’s wholly-owned development
programs for hepatitis B virus (HBV) and non-alcoholic steatohepatitis
(NASH) have been accepted for presentations at The International Liver
Congress™ (ILC) 2019, April 10-14, in Vienna, Austria.
New data will include a presentation on development candidate EDP-514,
Enanta’s core inhibitor for HBV that is expected to enter into a Phase 1
clinical study in the second half of 2019. There will also be
presentations focused on Enanta’s NASH program, featuring new data on
the FXR agonist EDP-305, and including in vivo data on EP-027315
and EP-026856, two prototype compounds from Enanta’s ASK-1 (apoptosis
signal-regulating kinase 1) inhibitor project.
The full ILC 2019 scientific program as well as the abstracts can be
found at https://ilc-congress.eu/programme-highlights/.
Further details will be available at the time of these presentations.
Poster Presentations at The International Liver Congress™ (ILC) 2019:
11, 2019 – 09:00 – 19:00
THU-084: “A comparative study of
anti-Fibrotic therapeutics using aptamer-based quantitative proteomics
in a rat model of non-alcoholic steatohepatitis cirrhosis”
Krishnan, United States
April 12, 2019 – 09:00 – 17:00
FRI-340: “In vivo effects of a
novel inhibitor of apoptosis signal-regulating kinase 1 in mouse models
of liver injury and metabolic disease”
FRI-191: “EDP-514, a novel HBV core inhibitor with potent antiviral
activity both in vitro and in
Kai Lin, United States
Enanta Pharmaceuticals is using its robust,
chemistry-driven approach and drug discovery capabilities to become a
leader in the discovery and development of small molecule drugs for the
treatment of viral infections and liver diseases. Enanta’s research and
development efforts are currently focused on the following disease
targets: respiratory syncytial virus (RSV), non-alcoholic
steatohepatitis (NASH)/ primary biliary cholangitis (PBC), and hepatitis
B virus (HBV).
Enanta’s research and development activities are funded by royalties
from HCV products developed under its collaboration with AbbVie.
Glecaprevir, a protease inhibitor discovered by Enanta, is now sold by
AbbVie in numerous countries as part of its newest treatment for chronic
hepatitis C virus (HCV) infection. This leading HCV regimen is sold
under the tradenames MAVYRET™ (U.S.) and MAVIRET™ (ex-U.S.)
(glecaprevir/pibrentasvir). Please visit www.enanta.com
for more information.